Close Menu

More articles about Business News

Taiwan-based Personal Genomics, which is developing a new single-molecule sequencing platform, has previously sued PacBio for patent infringement in the US.

The DeepChek-HIV assays are designed for settings running either Sanger sequencing or next-generation sequencing workflows, according to the company.

The new funds will be used, in part, to support ChromaCode's expansion into resource-limited communities in low- to middle-income nations.

Swiss firm DKSH will market and sell Ubiquitome's Liberty16 PCR-based platform in Australia, New Zealand, and other countries in the region.

10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.

The FDA granted Emergency Use Authorization for Everlywell's at-home nasal swab collection kit, which can be used with Fulgent and Assurance's tests.

Because of COVID-19, the San Diego-based firm said it was unable to ship new instruments and many users were unable to operate their existing ones.

The company, which launched the technology in September 2019, said in its Q4 earnings release that it received high marks from beta testers.

Since the Salt Lake City-based company launched its SARS-CoV-2 test in March, it has recorded COVID-19-related test and equipment sales of over $18 million.

The agreement marks Veracyte's first deal to expand the testing menu on the nCounter instrument since it acquired the rights to the platform from NanoString in December.

Novacyt said that the growing demand for its SARS-CoV-2 test, which was launched in late January, has significantly exceeded its expectations.

The first version of the platform, which the company submitted for Emergency Use Authorization to the US FDA last week, analyzes RNA extracted from a swab.

The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.

The firm's revenues fell to $2.2 million from $3.2 million in the same period the year before, missing the consensus Wall Street estimate of $3.0 million.

The company was able to increase its total revenue and test revenues despite accessioning fewer samples and fewer billable samples during the quarter.

The diagnostics firm is conducting a 1,000-person study to find T cell profiles associated with the immune response to COVID-19 and recovery from the disease.

The company will use proceeds from the offering to pay off debt related to other notes and to partially fund a redemption of other notes.

The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.

Pages

President Donald Trump announced the US would be leaving the World Health Organization, NBC News reports.

A study of Great Danes homes in on a genomic region linked to fearfulness.

CDC head says a new analysis indicates earlier testing wouldn't have caught viral spread, NPR reports.

In PLOS this week: gene expression and epigenetics of Indonesian populations, hookworm parasite secretome, and more.